HCV combo drug treats all genotypes in 8 weeks

Researchers have confirmed the efficacy of the pangenotypic antiviral combination of glecaprevir and pibrentasvir in patients with hepatitis C over eight weeks in a pooled analysis.

Data from nine phase 2 and phase 3 clinical trials was analysed to compare the effectiveness of eight and 12 weeks’ treatment with the combination at a dosage of  three 100mg glecaprevir/40mg pibrentasvir combination pills (Maviret, AbbVie) a day, or equivalent as separate pills.

The sustained virologic response 12 weeks after treatment (SVR12) was 98% in 965 patients treated for